• Ziqiu Chen, Caimei Wu, and Zhaoqi Huang.
• Guangzhou Medical University, Guangzhou, Guangdong, China; Cardiology Department, Guangdong ProvincialKey Laboratory of Major Obstetric Diseases, Guangdong Provincial Clinical Research Center for Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou, China.
• Prev Med. 2024 Apr 1; 181: 107909107909.

BackgroundBased on past epidemiological investigations, the cardiovascular role of estrogen replacement therapy (ERT) in postmenopausal women has always been controversial. The real efficacy of ERT for heart failure (HF) among postmenopausal women remains to be further investigated. This article is based on research into European and American populations.PurposeTo determine the impact of estrogen replacement therapy on HF using meta-analysis.Methods And MaterialElectronic literature was searched on Web of Science, PubMed, and Embase databases to identify randomized controlled trials (RCTs) comparing the hospitalization for heart failure between ERT users and non-users among postmenopausal women. Pairs of reviewers screened eligible articles independently, extracted data, and evaluated the risk of bias. Summary relative risks were estimated for the composite endpoint of first hospitalized heart failure and admission to the hospital for heart failure.ResultsA pooled study of five randomized controlled trials found that estrogen replacement therapy had no significant effect on the composite endpoint in postmenopausal women, with a relative risk of 1.02 (95% CI 0.94-1.10).ConclusionThis systematic review demonstrated that estrogen replacement therapy did not significantly change the risk of first hospitalized heart failure and admission to the hospital for heart failure in postmenopausal women.Copyright © 2024 The Third Affiliated Hospital of Guangzhou Medical University. Published by Elsevier Inc. All rights reserved.

16 keywords...

hide…